Diagnostic Accuracy of ELISA and Luminex Technology (xMAP) for the Quantitation of CSF Amyloid Beta 40 and 42 Peptides to differentiate Patients with Probable Alzheimer Disease (AD) from Elderly Non-demented Controls (P1.094)